Capricor Therapeutics, Inc. CAPR shares are trading higher on Friday. The company announced the long-term benefits of deramiocel for the treatment of duchenne muscular dystrophy (DMD).
What Happened: The biotechnology company said deramiocel increased cardiac function based on several different measures.
The study found improvements in left ventricular ejection fraction, left ventricular end systolic volume and left ventricular end diastolic volume. Capricor stated that these measures are considered highly applicable when projecting future outcomes.
The trial also demonstrated increased skeletal function, particularly increased performance of upper limb.
The company based these positive findings off the ongoing HOPE-2 open label extension study. Capricor is expected to present these results at the Parent Project Muscular Dystrophy (PPMD) Annual Conference on Saturday.
Related Link: Wall Street’s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
CAPR Price Action: Capricor Therapeutics shares are trading 4.39% higher at $4.84 at the time of writing per data from Benzinga Pro.
Image: Shutterstock/ REDPIXEL.PL
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
